Hilary Cassidy, Jennifer Slyne, Patrick O'Kelly, Carol Traynor, Peter J Conlon, Olwyn Johnston, Craig Slattery, Michael P Ryan, Tara McMorrow
Journal: Proteomics. Clinical applications 2016;9(5-6):574-85
PMID: 25951805
PURPOSE
Chronic allograft nephropathy (CAN) is widely accepted as the leading cause of renal allograft loss after the first year post transplantation. This study aimed to identify urinary biomarkers that could predict CAN in transplant patients.
EXPERIMENTAL DESIGN
The study included 34 renal transplant patients with histologically proven CAN and 36 renal transplant patients with normal renal function. OrbiTrap MS was utilized to analysis a urinary fraction in order to identify other members of a previously identified biomarker tree . This novel biomarker pattern offers the potential to distinguish between transplant recipients with CAN and those with normal renal function.
RESULTS
The primary node of the biomarker pattern was reconfirmed as β2 microglobulin. Three other members of this biomarker pattern were identified: neutrophil gelatinase-associated lipocalin, clusterin, and kidney injury biomarker 1. Significantly higher urinary concentrations of these proteins were found in patients with CAN compared to those with normal kidney function.
CONCLUSIONS AND CLINICAL RELEVANCE
While further validation in a larger more-diverse patient population is required to determine if this biomarker pattern provides a potential means of diagnosing CAN by noninvasive methods in a clinical setting, this study clearly demonstrates the biomarkers' ability to stratify patients based on transplant function.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Medical:
Miscellaneous:
Full Text Sources:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.